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CREATING A STAGE FOR 
INQUIRY AND BIOETHICS 
EDUCATION  
LYNN WEIN BUSH, PH.D., M.S., M.A. 
I. SETTING THE BIOETHICS STAGE  
Many bioethical challenges surround the promise of genomic technology 
and the power of genomic information,1 providing a rich context for critically 
exploring underlying bioethical traditions and foundations as well as the practice 
of multidisciplinary advisory committees. Karen and I long appreciated, 
independently and together, that the teaching of contemporary bioethics with 
creative approaches provides a significant opportunity to re-examine our 
disciplines’ underpinnings while addressing thorny issues by casting light on the 
implications of genomics. Of particular interest to Karen, and me, are 
 
© 2019 Lynn Wein Bush, Ph.D., M.S., M.A.  
 Division of Genetics and Genomics, Boston Children’s Hospital; Center for Bioethics, Harvard 
Medical School. I would like to thank Sue McCarty of the Thurgood Marshall Law Library at Maryland 
Carey Law for her expertise and patience in helping to format the references included in this piece. All of 
the material in this article was inspired by my collaboration with Karen, who so generously shared her 
scholarship, insights, and friendship with me this past decade. Segments from this article were paraphrased 
from my 2014 OUP Blog, Illuminating the Drama of DNA: Creating a Stage for Inquiry, 
https://blog.oup.com/2014/10/drama-dna-genomics-instruction/; or our book, The Drama of DNA: 
Narrative Genomics.  
 1. Eric D. Green & Marl S. Guyer, Nat’l Human Genome Research Inst., Charting a Course for 
Genomic Medicine from Base Pairs to Bedside, 470 NATURE 204 (2011); PRESIDENTIAL COMMISSION 
FOR THE STUDY OF BIOETHICAL ISSUES, PRIVACY AND PROGRESS IN WHOLE GENOME SEQUENCING 
(2012),  
https://bioethicsarchive.georgetown.edu/pcsbi/sites/default/files/PrivacyProgress508_1.pdf; 
PRESIDENTIAL COMMISSION FOR THE STUDY OF BIOETHICAL ISSUES, ANTICIPATE AND COMMUNICATE: 
ETHICAL MANAGEMENT OF INCIDENTAL AND SECONDARY FINDINGS IN THE CLINICAL, RESEARCH, AND  
DIRECT-TO-CONSUMER CONTEXTS (2013), 
https://bioethicsarchive.georgetown.edu/pcsbi/sites/default/files/FINALAnticipateCommunicate_PCSBI
_0.pdf; Robert C. Green et al., Exploring Concordance and Discordance for Return of Incidental Findings 
from Clinical Sequencing, 14 GENETICS MED. 405 (2012); Lynn W. Bush et al., Professional 
Responsibilities Regarding the Provision, Publication, and Dissemination of Patient Phenotypes in the 
Context of Clinical Genetic and Genomic Testing: Points to Consider—A Statement of the American 
College of Genetics and Genomics, 20 GENETICS MED. 169 (2018); Karen L. David et al., Patient Re-
Contact After Revision of Genomic Test Results: Points to Consider—A Statement of the American College 
of Genetics and Genomics, 21 GENETICS MED. 769 (2019). 
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controversial issues that call into question core values and assumptions inherent 
in bioethics analysis and necessitate interprofessional inquiry2—such as 
determining whether, what, to whom, when, and how genomic findings ought to 
be discovered and disclosed to individuals and their families,3 and whose voice 
matters in making these determinations, especially when children or pregnant 
women are involved.4 
Soon after we met a decade ago, Karen and I became a team, in scholarship 
and friendship, and developed narrative genomics.5 Using drama with 
fictionalized characters and dialogue as an engaging pedagogical approach, 
narrative genomics brings to life the diverse voices, varied contexts, and 
complex processes that encompass genomics as it evolves from research to 
clinical practice.6 Our interdisciplinary educational technique focuses on 
inherent challenges currently posed by the comprehensive interrogation and 
analysis of DNA and illuminates ethical, legal, social, psychological, and policy 
issues7, providing a stage to reflect on the controversies together.  
As a bioethics teaching method,8 narrative genomics highlights the breadth 
of individuals affected by next-gen technologies—the conversations among 
professionals and families—bringing to life the spectrum of emotions and 
 
 2. James P. Evans, Finding Common Ground, 15 GENETICS MED. 852 (2013); Robert C. Green et 
al., ACMG Recommendations for Reporting of Incidental Findings in Clinical Exome and Genome 
Sequencing, 15 GENETICS MED. 565 (2013); American College of Medical Genetics and Genomics, 
Incidental Findings in Clinical Genomics: A Clarification, 15 GENETICS MED. 664 (2013). 
 3. Amy L. McGuire et al., Point-Counterpoint: Ethics and Genomic Incidental Findings, 340 
SCIENCE 1047 (2013); Susan M. Wolf et al., Point-Counterpoint: Patient Autonomy and Incidental 
Findings in Clinical Genomics, 340 SCIENCE 1049 (2013); Catherine Gliwa & Benjamin E. Berkman, Do 
Researchers Have an Obligation to Actively Look for Genetic Incidental Findings?, AM. J. BIOETHICS, 
Feb. 2013, at 32; Gail E. Henderson et al., What Research Ethics Should Learn from Genomics and Society 
Research: Lessons from the ELSI Congress of 2011, 40 J.L. MED. &ETHICS 1008 (2012). 
 4. Lynn Bush, In the Best Interest of the Child: Psychological and Ethical Reflections on Traditions, 
Contexts, and Perspectives in Pediatric Clinical Genomics, AM. J. BIOETHICS, Mar. 2014, at 16; James P. 
Evans, Return of Results to the Families of Children in Genomic Sequencing: Tallying Risks and Benefits, 
15 GENETICS MED. 435 (2013); Ellen Wright Clayton et al., Addressing the Ethical Challenges in Genetic 
Testing and Sequencing of Children, AM. J. BIOETHICS, Mar. 2014, at 3; Christine C. Grady & Colleen C. 
Denny, Ethical Issues in Research Involving Women, in THE OXFORD TEXTBOOK OF CLINICAL RESEARCH 
ETHICS 407 (Ezekiel J. Emanuel et al. eds., 2008). 
 5. KAREN H. ROTHENBERG & LYNN WEIN BUSH, THE DRAMA OF DNA: NARRATIVE GENOMICS 
(2014). 
 6. Eric D. Green, Foreword, in ROTHENBERG & BUSH, supra note 5; Teri A. Manolio et al., 
Implementing Genomic Medicine in the Clinic: The Future Is Here, 15 GENETICS MED. 258 (2013); Laura 
L. Rodriguez et al., Research Ethics: The Complexities of Genomic Identifiability, 339 SCIENCE 275 
(2013). 
 7. Karen H. Rothenberg & Lynn W. Bush, Genes and Plays: Bringing ELSI Issues to Life, 14 
GENETICS MED. 274 (2012); Lynn W. Bush & Karen H. Rothenberg, Dialogues, Dilemmas, and 
Disclosures: Genomic Research and Incidental Findings, 14 GENETICS MED. 293 (2012). 
 8. METHODS IN MEDICAL ETHICS (Jeremy Sugarman & Daniel P. Sulmasy eds., 2d ed. 2010); Jules 
Odendahl-James, Book Review, AM. J. BIOETHICS, Dec. 2016, at W17 (reviewing ROTHENBERG & BUSH, 
supra note 5). 
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challenges that envelope genomics. Controversies over sequencing in children9 
and consent issues10 have brought fundamental ethical theses to the stage to be 
re-examined,11 further fueling our belief in drama as an interdisciplinary 
pedagogical approach to explore how society evaluates, processes, and shares 
genomic information that may implicate future generations. With a mutual 
interest in enhancing dialogue and understanding about multi-faceted 
implications raised by generating and sharing genomic information, and with our 
diverse backgrounds and perspectives, we have been collaboratively weaving 
dramatic narratives to enhance the bioethics educational experience within 
varied professional contexts and academic levels.12  
Dramatizations of fictionalized individual, familial, and professional 
relationships that surround the ethical landscape of genomics create the potential 
to stimulate bioethical reflection and new perceptions amongst “actors” and the 
audience, sparking the moral imagination13 through the lens of others. By casting 
light on all “the storytellers” and the complexity of implications inherent with 
this powerful technology, our dramatic narratives create vivid scenarios through 
which to imagine the challenges faced on the genomic path ahead, critique the 
application of bioethical traditions in context, and re-imagine alternative 
paradigms. 
Building upon the legacy of case vignettes in clinical teaching, and inspired 
by “readers’ theater,”14 “narrative ethics,”15 and “narrative medicine”16 as 
approaches that helped us expand the analyses to implications of genomic 
technologies, our experiences suggested similar value for bioethics education 
within the translational research and public policy domain. While drama had 
 
 9. Laine Friedman Ross et al., Technical Report: Ethical and Policy Issues in Genetic Testing and 
Screening of Children, 15 GENETICS MED. 234 (2013); ROTHENBERG & BUSH, supra note 5; Green et al., 
supra note 2; American Academy of Pediatrics, Committee on Bioethics, Committee on Genetics, 
American College of Medical Genetics, Ethical and Policy Issues in Genetic Testing and Screening of 
Children, 131 PEDIATRICS 620 (2013). 
 10. Lynn W. Bush et al., Pediatric Clinical Exome/Genome Sequencing and the Engagement 
Process: Encouraging Active Conversation with the Older Child and Adolescent: Points to Consider—A 
Statement of the American College of Genetics and Genomics, 20 GENETICS MED. 692 (2018). 
 11. Wylie Burke et al., Recommendations for Returning Genomic Incidental Findings? We Need To 
Talk!, 15 GENETICS MED. 854 (2013). 
 12. A Summary of MOLLY COOKE ET AL., EDUCATING PHYSICIANS: A CALL FOR REFORM OF 
MEDICAL SCHOOL AND RESIDENCY (2010), http://archive.carnegiefoundation.org/elibrary/educating-
physicians-summary.html. 
 13. R.S. DOWNIE & JANE MACNAUGHTON, BIOETHICS AND THE HUMANITIES: ATTITUDES AND 
PERCEPTIONS (2007). 
 14. TODD L. SAVITT, MEDICAL READERS’ THEATER: A GUIDE AND SCRIPTS (2002); Nancy King & 
Richard Robeson, Dramatic Arts Casuistry in Bioethics Education and Outreach (paper presented at ELSI 
Congress; 2011; Chapel Hill, NC). 
 15. STORIES MATTER: THE ROLE OF NARRATIVE IN MEDICAL ETHICS (Rita Charon & Martha 
Montello eds., 2002); Martha Montello ed., Narrative Ethics: the Role of Stories in Bioethics, 44 
HASTINGS CTR. REP. (Special issue 2014). 
 16. RITA CHARON NARRATIVE MEDICINE: HONORING THE STORIES OF ILLNESS (2006). 
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often been utilized in academic and medical settings to facilitate empathy and 
spotlight ethical and legal controversies such as end-of-life issues, 
professionalism, and health law,17 we realized there were few dramatizations 
focusing on exome/genome sequencing.18 
We initially collaborated on the creation of a short vignette-play in the 
context of genomic research and the informed consent process that was 
performed by colleagues at the NHGRI-ELSI Congress, followed by excerpts 
selected from existing theatre.19 The response by “actors” and audience fueled 
us to present additional original dramatic scenarios as well as expand upon 
Karen’s already significant contributions to the field exploring existing theatrical 
dialogues, with both methods continuing to engage interdisciplinary 
professionals at conferences and academic institutions, nationally and 
internationally. 
Since a growing number of colleagues inquired about using our plays in 
their classrooms, we authored a book based on adaptations of six original and 
twelve existing plays.20 Designed to enhance teaching, The Drama of DNA: 
Narrative Genomics was structured to provide an analytical foundation to 
reinforce the fact that many complex bioethics issues surface repeatedly in 
varying contexts and can become increasingly more controversial, for example 
as experienced with ethical-legal debates surrounding the initial ACMG 
recommendations on the return of incidental findings.21 
 
 17. Melissa McCullough, Bringing Drama into Medical Education, 379 LANCET 512 (2012); 
Johanna Shapiro & Lynn Hunt, All the World’s a Stage: The Use of Theatrical Performance in Medical 
Education, 37 MED. EDUC. 922 (2003); THE PICTURE OF HEALTH: MEDICAL ETHICS AND THE MOVIES 
(Henry Holt et al. eds., 2011); Matthew J. Czarny et al., Bioethics and Professionalism in Popular 
Television Medical Dramas, 36 J. MED. ETHICS 203 (2010); Karl Lorenz et al., End-of-Life Education 
Using the Dramatic Arts: The Wit Educational Initiative, 79 ACAD. MED. 481 (2004). 
 18. Lynn W. Bush & Karen H. Rothenberg, It’s So Complicated! Genomic Research & Incidental 
Findings, online supplement to Lynn W. Bush & Karen H. Rothenberg, Dialogues, Dilemmas, and 
Disclosures: Genomic Research and Incidental Findings, 14 GENETICS MED. 293 (2012), 
https://www.nature.com/articles/gim201172#s1 [hereinafter Bush & Rothenberg, Complicated]; Lynn W. 
Bush & Karen H. Rothenberg, It’s Not That Simple! Genomic Research & the Consent Process, online 
supplement to Karen H. Rothenberg & Lynn W. Bush, Genes and Plays: Bringing ELSI Issues to Life, 14 
GENETICS MED. 274 (2012),  
https://staticcontent.springer.com/esm/art%3A10.1038%2Fgim.2011.47/MediaObjects/41436_2012_BF
gim201147_MOESM1_ESM.pdf [hereinafter Bush & Rothenberg, Simple]; MAHALA YATES STRIPLING, 
BIOETHICS AND MEDICAL ISSUES IN LITERATURE: EXPLORING SOCIAL ISSUES THROUGH LITERATURE 
(2005); KIRSTEN SHEPHERD-BARR, SCIENCE ON STAGE: FROM DOCTOR FAUSTUS TO COPENHAGEN 
(2006). 
 19. Jill M. Oliver & Amy L. McGuire, Exploring the ELSI Universe: Critical Issues in the Evolution 
of Human Genomic Research, 3 GENOME MED. art. no. 38 (2011); Gail E. Henderson et al., What Research 
Ethics Should Learn from Genomics and Society Research: Lessons from the ELSI Congress of 2011, 40 
J.L. MED. & ETHICS 1008 (2012). 
 20. ROTHENBERG & BUSH, supra note 5. 
 21. See Evans supra note 2; Green et al., supra note 2; American College of Medical Genetics and 
Genomics, supra note 2. 
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Because narrative genomics is a pedagogical approach intended to facilitate 
discourse as well as provide reflection on the interrelatedness of the cross-
disciplinary issues posed, we begin with a content analysis of critical issues, then 
ground our original dramatic scenarios in current scholarship and consult with 
experts to ensure scientific accuracy. We also provide extensive references in the 
book and pose focused bioethics questions to complement and enhance the 
classroom experience.  
Bioethical issues and controversies can also be brought to life when 
teaching incorporates dramatizations from existing theatre whether to highlight 
thematically, or illuminate the historical path to the genomics revolution from an 
ethical, legal, societal perspective as Karen had previously done, including 
“From Eugenics to the “New Eugenics: The Play’s the Thing,” and with our 
broader analysis of 46 plays across three centuries for our monograph-anthology, 
Manipulating Fate: Medical Innovations, Ethical Implications, Theatrical 
Illuminations.22 Varying iterations of these theatrical narratives have been 
experienced internationally to enhance bioethical insight and facilitate 
interdisciplinary dialogue largely thanks to Karen, who has particular expertise 
using theatre as a platform for teaching and inquiry over decades, perhaps most 
notably at the Smithsonian.23 
II. PROCESS IN CONTEXT AND CONTROVERSY 
As our bioethical exploration of the drama of DNA focuses the imagination 
on exome/genome sequencing, the complexities and processes of integrating 
genomic research and medicine are illuminated in a variety of contexts. These 
contemporary bioethical issues are brought to life through fictionalized 
characters and their dramatic narratives, illustrating potential benefits and 
decision-making dilemmas facing individuals, families, and professionals with 
comprehensive genome technology and the information it generates. Our 
characters cover thorny ethical terrain traversing from prenatal testing24 to 
 
 22. Karen H. Rothenberg, From Eugenics to the ‘New’ Genetics: “The Play’s the Thing,” 79 
FORDHAM L. REV. 407 (2010); Karen H. Rothenberg & Lynn W. Bush, Manipulating Fate: Medical 
Innovations, Ethical Implications, Theatrical Illuminations, 13 HOUS. J. HEALTH L. & POL’Y 1 (2012). 
 23. Raymond MacDougall, NHGRI Workshop Spotlights the Connection Between Genomics and 
Theater, NAT’L HUM. GENOME RES. INST. (Apr. 30, 2014), https://www.genome.gov/27557019/nhgri-
workshop-spotlights-the-connection-between-genomics-and-theater. 
 24. WOMEN AND PRENATAL TESTING: FACING THE CHALLENGES OF GENETIC TECHNOLOGIES 
(Karen H. Rothenberg & Elizabeth J. Thomson eds., 1994); PRENATAL TESTING AND DISABILITY RIGHTS 
(Erik Parens & Adrienne Asch eds., 2000); Ilana R. Yurkiewicz et al., Prenatal Whole-Genome 
Sequencing—Is the Quest to Know a Fetus’s Future Ethical?, 370 NEW ENG. J. MED. 195 (2014); Diana 
W. Bianchi, Cherchez la Femme: Maternal Incidental Findings Can Explain Discordant Prenatal Cell-
Free DNA Sequencing Results, 20 GENETICS MED. 910 (2018). 
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newborn screening and sequencing healthy infants on a population-level25 to 
whole genome sequencing children.26 
Through narrative genomics, we aim to raise awareness that preferences 
and tolerance for uncertainty vary within and across families, and depending on 
cultural and other demographic variables, the way in which genomic information 
is received and shared will differ, as will expectations.27 Moreover, cognizant 
that perspectives can dramatically shift depending on the nuances and context 
presented, we purposefully select characters’ age-ranges to highlight the 
additional responsibility required when considering sharing genomic 
information attained from families that include pregnant women and fetuses, 
newborns, and children28 with varying levels of assent.29  
By highlighting variation of voices on issues and contextual nuances, 
including the commonalities and distinctions between research, clinical, and 
 
 25. Karen and I have presented on ELSI issues in Newborn Screening and Sequencing in many 
venues over the past decade. For example: Navigating the Thorny Landscape on the Path from Newborn 
Screening to Genome Sequencing. ASHG 2014 Evening Premiere, Presenter. actor-panelists E Green, H 
Rehm, J Evans, B Koenig, R Truog, W Burke, R Nussbaum, C Bustamonte, J Botkin; Script/Video 
ASHGweb, open access NHGRI. ROTHENBERG & BUSH, supra note 5, at 31–56; Ellen Wright Clayton, 
Currents in Contemporary Ethics. State Run Newborn Screening in the Genomic Era, or How to Avoid 
Drowning when Drinking from a Fire Hose, 38 J.L. MED. & ETHICS 697 (2010); Jonathan S. Berg et al., 
Newborn Sequencing in Genomic Medicine and Public Health, 139 PEDIATRICS e20162252 (2017); Aaron 
J. Goldenberg et al., Including ELSI Research Questions in Newborn Screening Pilot Studies, 21 
GENETICS MED. 525 (2019); Josephine Johnston et al., Sequencing Newborns: A Call for Nuanced Use of 
Genomic Technologies, HASTINGS CTR. REP., July/Aug. 2018, at S2. 
 26. Wylie Burke & Douglas S. Diekema, Ethical Issues Arising from the Participation of Children 
in Genetic Research, 149 J. PEDIATRICS S34 (2006); Isaac S. Kohane, No Small Matter: Qualitatively 
Distinct Challenges of Pediatric Genomic Studies, 3 GENOME MED. art. no. 62 (2011); Colleen M. 
McBride & Alan E. Guttmacher, Commentary: Trailblazing a research Agenda at the Interface of 
Pediatrics and Genomic Discovery—a Commentary on the Psychological Aspects of Genomics and Child 
Health, 34 J. PEDIATRIC. PSYCHOL. 662 (2009). 
 27. Karen and I serve in an advisory role (to H3Africa IFGeneRA PI Jantina De Vries), helping adapt 
our narrative genomics approach for a Cape Town-Botswana research context. The study examines ethical 
issues regarding feedback of individual genetic research results, exploring preferences of parents whose 
children have neurodevelopmental conditions, mostly autism, using our Drama of DNA method to foster 
engagement and understanding of ethical challenges, incl strong ancillary care expectations, belief in 
witchcraft as explanatory illness model, and resource-limited setting impacting medical actionability. 
 28. Additional protections for pregnant women, human fetuses, and human neonates involved in 
research. 45 C.F.R. § 46.201-46.207 (2012). 
 29. Benjamin S. Wilfond & Douglas S. Diekema, Engaging Children in Genomics Research: 
Decoding the Meaning of Assent in Research, 14 GENETICS MED. 437 (2012); Lynn W. Bush et al., 
Pediatric Clinical Exome/Genome Sequencing and the Engagement Process: Encouraging Active 
Conversation with the Older Child and Adolescent: Points to Consider—A Statement of the American 
College of Genetics and Genomics, 20 GENETICS MED. 692 (2018). 
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public health domains,30 screening and diagnostic testing,31 and the quality of 
information and counseling32 generated by genomic technologies, our narrative 
genomics approach encourages interprofessional communication and 
collaboration33 whether in the classroom or large professional conference, locally 
or globally.  
We reflect on the reality that as the evolution of exome/genome sequencing 
progresses exponentially from research to clinical medicine and public health 
screening, so too does the discovery of incidental/secondary findings and ethical 
complexities.34 Further complicating the decision-making and return of results 
process, it often is the case that the original question for which genomic study 
was indicated will go unanswered or be uncertain.35  
Our scenarios also illuminate that, unlike some diagnostic or screening 
methods, comprehensive genomic sequencing can reveal information that 
extends beyond the individuals to include blood relatives and ancestral groups, 
and thus, anticipation of the implications necessitates additional forethought.36 
The sharing of secondary results amongst individuals, professionals, and families 
that are attained in both genomic research and clinical medicine remains 
controversial,37 and the need to clarify definitions such as variable penetrance 
and susceptibility is essential. There is great debate as to what revelations 
constitute urgency for disclosure and who should decide, as well as what findings 
are deemed clinically relevant, actionable, or predictable.38 
The fictionalized characters are designed to represent many perspectives, 
spotlighting less than ideal professional practices in somewhat caricature-fashion 
 
 30. Christine Grady & David Wendler, Making the Transition to a Learning Health Care System. 
Commentary, HASTINGS CTR. REP., Jan./Feb. 2013, at S32; Emily A. Largent et al., Can Research and 
Care Be Ethically Integrated? Commentary, HASTINGS CTR. REP., July/Aug. 2011, at 37; Mildred Z. 
Solomon & Ann Bonham, eds., Special Issue, Ethical Oversight of Learning Health Care Systems, 
HASTINGS CTR. REP. Jan./Feb. 2013, at S2. 
 31. Wylie Burke et al., Genetic Screening, 33 EPIDEMIOLOGIC REVS. 148 (2011). 
 32. Barbara A. Bernhardt et al., An Exploration of Genetic Counselors’ Needs and Experiences with 
Prenatal Chromosomal Microarray Testing, 23 J. GENETIC COUNSELING 139 (2013). 
 33. Diane R. Bridges et al., Interprofessional Collaboration: Three Best Practice Models of 
Interprofessional Education, 16 MED. EDUC. ONLINE art. no. 6035 (2011). doi:10.3402/meo.v16i0.6035. 
 34. James P. Evans, When Is a Medical Finding “Incidental”?, 15 GENETICS MED. 515 (2013); 
Susan M. Wolf, The Past, Present, and Future of the Debate over Return of Research Results and 
Incidental Findings, 14 GENETICS MED. 355 (2012). 
 35. Rachel B. Ramoni et al., The Undiagnosed Diseases Network: Accelerating Discovery About 
Health and Disease, 100 AM. J. HUM. GENETICS 185 (2017). 
 36. Ben Chan et al., Genomic Inheritances: Disclosing Individual Research Results from Whole-
Exome Sequencing to Deceased Participants’ Relatives, 12 AM. J. BIOETHICS, no. 10, 2012, at 1. 
 37. Rachel B. Ramoni et al., Experiences and Attitudes of Genome Investigators Regarding Return 
of Individual Genetic Test Results, 15 GENETICS MED. 882 (2013). 
 38. Leslie G. Biesecker, Incidental Variants Are Critical for Genomics, 92 AM. J. HUM. GENETICS 
648 (2013); Christopher A. Cassa et al., Large Numbers of Genetic Variants Considered to be Pathogenic 
Are Common in Asymptomatic Individuals, 34 HUM. MUTATION 1216 (2013). 
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as well as all-too-real procedural challenges. Our dialogue emphasizes that 
neither the clinician-researcher nor the individual can always predict whether 
their preferences for the return of results will change or who will bear the burden 
and distress from the return of unanticipated findings.39 Furthermore opt-out/in 
clauses to receive genomic findings are not always provided, with little 
consensus regarding under what circumstances, if any, a consent form’s request 
“not to know” may go un-honored.  
Karen and I feel strongly, mirrored by some of our characters, that next-
generation sequencing raises particular challenges when children,40 especially 
otherwise “unaffected” children, are faced with findings that raise novel concerns 
about their future.41  As investigations involving minors engender even more 
complex ethical and psychological challenges, the need for heightened 
sensitivity by professionals becomes magnified, as does the unsettling nature for 
researchers and clinicians.42 Differential approaches must be weighed not only 
to consider whether, but to whom and when, results may be disclosed. 
III. THE DRAMA OF DNA 
With these debates and dilemmas as our backdrop, the scenario for one of 
our vignette-plays and book chapters43 spotlights Whole Genome Sequencing 
and the need for ethics consultations in a variety of contexts, including IRBs and 
genomics advisory committees. The drama particularly highlights the roles 
professionals should play within each group to minimize psychosocial harm, 
ideally in advance of genomic testing. This dialogue brings to life significant 
challenges with the process and systemic questions raised when “a plan” does 
 
 39. Laura M. Beskow & Wylie Burke, Offering Individual Genetic Research Results: Context 
Matters, 2 SCI. TRANSLATIONAL MED. 38cm20 (2010); James P. Evans & Barbra B. Rothschild, Return 
of Results: Not that Complicated?, 14 GENETICS MED. 358 (2012); Amy L. McGuire et al., Returning 
Genetic Research Results: Study Type Matters, 10 PERSONALIZED MED. 27 (2013). 
 40. Anya E.R. Prince & Benjamin E. Berkman, When Does an Illness Begin: Genetic Discrimination 
and Disease Manifestation, 40 J.L. MED. ETHICS 655 (2012); Jennifer M. Kwon & Robert D. Steiner, 
“I’m Fine; I’m Just Waiting for my Disease”: The New and Growing Class of Presymptomatic Patients, 
77 NEUROLOGY 522 (2011); Bush, supra note 4. 
 41. Christopher H. Wade et al., Effects of Genetic Risk Information on Children’s Psychosocial 
Wellbeing: A Systematic Review of the Literature, 12 GENETICS MED. 317 (2010); Annelien L. 
Bredenoord et al., Next-Generation Sequencing: Does the Next Generation Still Have a Right to an Open 
Future?, 14 NATURE REVS. GENETICS 306 (2013); Dena S. Davis, Genetic Dilemmas and the Child’s 
Right to an Open Future, HASTINGS CTR. REP., Mar./Apr. 1997, at 7. 
 42. Kristien Hens et al., The Return of Individual Research Findings in Paediatric Genetic Research, 
37 J. MED. ETHICS 179 (2011); Ruqayyah Abdul-Karim et al., Disclosure of Incidental Findings from 
Next-Generation Sequencing in Pediatric Genomic Research, 131 PEDIATRICS 564 (2013). 
 43. ROTHENBERG & BUSH, supra note 5, at 11–30; ROTHENBERG & BUSH, supra note 5, at 61–80. 
Karen and I used iterations of these plays and ethical analysis in 2013-2015 as invited faculty presenters 
at Advancing Ethical Research, PRIM&R Annual Conference. Actor-panelists include C Grady, P 
O’Rourke, R (Skip) Nelson, J Botkin, S Joffe, S Kornetsky, B Bierer, M Barnes. All videos and scripts 
available for educational purposes at PRIM&R (context peds rare disorder; autism). 
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not adequately consider potential risks. Along with exploring reactions toward 
planning protocols in anticipation of results generated from the genomic study, 
the narratives illustrate inherent tensions among professionals and the need for 
guidance from institutional boards, advisory committees, and professional 
societies. 
We showcase the practical application of the issues with distinctions that 
are context-driven and relationship-oriented. Our earliest play and sequel44 sheds 
light on the complexity of emotions, reactions, and implications throughout the 
informed consent process and during disclosure of genomic information. The 
vignette illuminates some of the challenges that may arise from the 
multidimensional role of the clinical geneticist-researcher when recruiting a 
long-standing patient and family for participation in a genomic study. The 
narrative commences by illustrating It’s Not That Simple!,45 with dialogue that 
focuses on decision-making dilemmas often facing family members during the 
informed consent process for genomic research and medicine, and concludes 
with some of the professional, personal, and familial dilemmas surrounding the 
reporting of genomic findings to illuminate that It’s So Complicated!46 Such 
issues considered in the play include the blurring of boundaries between genomic 
research and clinical practice, the therapeutic misconception, privacy and 
confidentiality, biobanking, reporting incidental findings to unaffected children, 
the role of assent, and broader implications for blood relatives and ethnic 
communities. 
IV. REFLECTIONS  
Whilst Karen and I are often vocal regarding our differing perspectives on 
these issues, which in part shapes some of our characters and dialogue, we fully 
share the belief that the sensory and visceral impact of experiencing dramatic 
narrative is powerful, and the synergy between the application of genomic 
technologies and the value-laden choices these innovations create raise 
fundamental questions that center on complex ethical dilemmas for individuals, 
families, and society. Because values among individuals are so diverse and fluid, 
the powerful role of relationships within a family varies across a continuum, and 
different judgments about “what is normal?” are shaped by our experiences and 
cultural expectations, which directly impact how we frame our identities and 
 
 44. ROTHENBERG & BUSH, supra note 5, at 31–45; Karen and I used iterations of the play and ethical 
analysis in 2015 at Johns Hopkins University-Berman Institute of Bioethics. Presentation-panel with 
videoed play for teaching. Session open access on JHU Berman website. We also presented at The 
Presidential Commission of Bioethics Lunchtime Speaker Series for an invited interactive play and lecture 
as co-commentators. 
 45. See Bush & Rothenberg, Simple, supra note 18. 
 46. See Bush & Rothenberg, Complicated, supra note 18. 
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those of others, including constructs of dis-abilities – all powerful issues 
influenced by genomics and ripe for teaching bioethics with dramatic scenarios.  
We strongly endorse the position that the complexity of decision-making 
and these contemporary bioethical issues is powerfully brought to life through 
narratives, “just because it is not our life, places us in a moral position that is 
favorable for perception and it shows us what it would be like to take up that 
position in life.”47 As Karen is uniquely poised to know given her past role as 
senior advisor on Genomics and Society to the NHGRI Director, by facilitating 
discourse and raising more questions than answers on difficult issues, narrative 
genomics links the opportunities and concerns of next-gen technologies with a 
creative bioethics pedagogical approach for learning from one another. 
 
 
 47. MARTHA C. NUSSBAUM, LOVE’S KNOWLEDGE: ESSAYS ON PHILOSOPHY AND LITERATURE 
(1990). 
